Eton Pharmaceuticals(ETON) - 2019 Q1 - Earnings Call Presentation

Company Overview - Eton Pharmaceuticals is a specialty pharmaceutical company focused on improving existing medicines to address unmet patient needs[5] - The company utilizes the 505(b)(2) NDA pathway for low-cost, low-risk development of innovative branded drugs[5] - Eton has a diversified pipeline of 12 products under development, with four products filed with the FDA and three additional NDA's expected to be filed in 2019[5] - The company expects to become a commercial revenue company in 2019[5] Product Pipeline - Four candidates are currently filed with the FDA, and three additional filings are expected in 2019[16] - The company is developing six injectable product candidates for administration in the hospital setting[16] - Eton is also developing four innovative oral liquid formulations of molecules that are only FDA-approved in oral solid form[18] - EM-100 ophthalmic solution, an innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis, has been filed with the FDA and is expected to be approved in 2019[20] - The U S allergic conjunctivitis ophthalmic market is >$600 million annually[20] Financial Information - As of April 1, 2019, the stock price was $7 95[23] - As of March 15, 2019, shares outstanding were 17 6 million[23] - As of April 1, 2019, the market cap was $140 million[23] - As of December 31, 2018, the cash balance was $26 7 million[23]